Elicio Therapeutics, Inc. (ELTX)

Elicio Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $12.00 - $14.00
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
Market Cap180.42M
Revenue (ttm)n/a
Net Income (ttm)-18.90M
Shares Out13.88M
EPS (ttm)-1.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ELTX

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated. Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system - the lymph nodes. We believe this site-specific delivery of disease-specific antigens, a...

IndustryPharmaceutical Preparations
Founded2011
CEORobert Connelly
Employees22
Stock ExchangeNASDAQ
Ticker SymbolELTX
Full Company Profile

Financial Performance

Financial Statements

News

Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtay...

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, announ...

Other symbols:REGN
2 days ago - GlobeNewsWire

Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion ...

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today ...

6 days ago - GlobeNewsWire

Elicio Therapeutics Moves into Boston's Seaport District and Provides Update on Programs

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, toda...

2 months ago - GlobeNewsWire

Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Im...

CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other disea...

6 months ago - GlobeNewsWire

Elicio Therapeutics Announces First Patient Dosed in the ELI-002 (AMPLIFY-201) study in KRAS-Driven Cancers

CAMBRIDGE Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseas...

7 months ago - GlobeNewsWire